Welcome to our dedicated page for Arcadia Bioscien SEC filings (Ticker: RKDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arcadia Biosciences, Inc. (Nasdaq: RKDA) SEC filings page on Stock Titan brings together the company’s official regulatory documents, offering a detailed view of how management reports its business, finances, and corporate actions. As a producer and marketer of plant-based and innovative wellness products with a focus on Zola coconut water and related assets, Arcadia uses its filings to describe revenue composition, operating expenses, asset sales, capital structure, and governance matters.
Key filings for RKDA include annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide narrative and tabular disclosures about continuing operations centered on Zola coconut water, discontinued operations related to former brands such as GoodWheat, and the impact of gains on asset sales, credit losses, and changes in fair value of financial instruments. These reports also discuss risk factors, accounting policies, and other items relevant to long-term investors.
Arcadia frequently files current reports on Form 8-K to describe material events. Recent 8-K filings cover topics such as inducement offer letter agreements for the exercise of preferred investment options, the issuance of new preferred investment options and placement agent options, scheduling of the 2025 annual meeting, changes in executive roles, and the previously proposed and later terminated Securities Exchange Agreement with Roosevelt Resources, LP. These documents explain transaction terms, option mechanics, and related covenants.
The company’s proxy materials, including the definitive proxy statement on Schedule 14A, outline director elections, advisory votes on executive compensation, audit firm ratification, and the conduct of virtual stockholder meetings. They also describe board composition, compensation practices, and stockholder voting procedures.
On Stock Titan, RKDA filings are updated as they are made available through EDGAR, and AI-powered summaries help explain the structure and implications of complex documents such as 10-Ks, 10-Qs, 8-Ks, and proxy statements. Investors can quickly scan for disclosures about Arcadia’s wellness-focused operations, Zola coconut water revenues, asset monetization, option and warrant terms, and stockholder meeting matters, while retaining access to the full underlying filings for deeper review.
Arcadia Biosciences, Inc. disclosed that its chief financial officer and principal accounting officer, Mark Kawakami, has tendered his resignation as an officer and employee, effective September 12, 2025. The company states that his resignation is not due to any disagreement with Arcadia or its independent auditors on operations, policies, financial statements, or accounting practices, and notes he may assist after his departure as an advisor or consultant if requested.
Effective upon his resignation, the Board has appointed President and Chief Executive Officer Thomas J. Schaefer as Interim Chief Financial Officer and principal accounting officer. Schaefer previously served as Arcadia’s Chief Financial Officer from January 2023 until becoming President and CEO in July 2024, and his selection was not made pursuant to any arrangement with another person. His compensation is unchanged.
The filing also reiterates details of Arcadia’s proposed all-stock exchange transaction with Roosevelt Resources, LP, for which a Form S-4 registration statement has been filed and amended, and urges investors to read the registration statement and proxy statement/prospectus once available, as they will contain important information about the transaction and related risks.
Arcadia Biosciences (RKDA) disclosed several material corporate and accounting developments in its Form 10-Q. The company amended an Exchange Agreement and filed a Form S-4 related to an equity issuance, extending the agreements termination date to August 15, 2025. As of June 30, 2025 the company had 150,000,000 shares authorized and 1,367,040 shares issued and outstanding (1,364,940 at December 31, 2024).
The company treated the sale of its GoodWheat business as a discontinued operation under ASC 205-20, recognizing a $1,500 loss in the second quarter of 2024. A contingent liability tied to prior Anawah technology obligations of $2.0 million was eliminated as of June 30, 2025 after program abandonments and transfers. The company recorded an additional right-of-use asset and lease liability of $86,000 related to a lease renewal and later terminated that facility lease effective July 2024.
Equity plans changed: the 2015 Plan terminated for future awards in May 2025; 338,341 shares remained reserved under the 2015 Plan as of June 30, 2025. The company faces a Proposition 65-related BPA lawsuit amended May 23, 2025, and answered the complaint on July 22, 2025, denying liability. Managements CODM evaluates performance using consolidated net (loss) income.
Arcadia Biosciences, Inc. filed a current report to furnish its financial results for the second quarter ended June 30, 2025. The company issued a press release and detailed financial information, attached as Exhibits 99.1 and 99.2, covering second-quarter 2025 performance and business highlights.
The report also reiterates the previously announced plan for an all-stock exchange transaction with Roosevelt Resources, LP under a Securities Exchange Agreement. Arcadia has filed a Registration Statement on Form S-4, including a preliminary proxy statement/prospectus, and a pre-effective amendment filed on July 31, 2025. After the Registration Statement is declared effective, Arcadia intends to mail a definitive proxy statement/prospectus to stockholders for a vote on the proposed transaction.